343 related articles for article (PubMed ID: 34756755)
1. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
Baker S; Mou B; Jiang W; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Berrang T; Bang A; Chng N; Matthews Q; Tyldesley S; Olson RA
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):849-855. PubMed ID: 36302495
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy.
Chen HJ; Tu CY; Hsia TC; Fang HY; Chen CH; Chen SC; Li CH; Liao YM; Hsieh CY; Lein MY; Liang JA; Chien CR
Anticancer Res; 2020 Oct; 40(10):5895-5899. PubMed ID: 32988920
[TBL] [Abstract][Full Text] [Related]
6. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy.
Thomas MC; Chen YH; Fite E; Pangilinan A; Bubelo K; Spektor A; Balboni TA; Huynh MA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):747-761. PubMed ID: 35840113
[TBL] [Abstract][Full Text] [Related]
7. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
Patel PH; Chaw CL; Tree AC; Sharabiani M; van As NJ
World J Urol; 2019 Dec; 37(12):2615-2621. PubMed ID: 31346760
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
10. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
12. Oligometastatic Prostate Cancer Treated with Stereotactic Body Radiation Therapy: The Role of Three-Dimensional Tumour Volume in Patient Survival.
Franzese C; Lucchini R; Roghi M; Badalamenti M; Baldaccini D; Comito T; Franceschini D; Navarria P; Di Cristina L; Lo Faro L; Galdieri C; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e649-e656. PubMed ID: 37775459
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
Franzese C; Di Brina L; D'Agostino G; Franceschini D; Comito T; De Rose F; Tozzi A; Navarria P; Scorsetti M
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2469-2479. PubMed ID: 31444549
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
15. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.
Huynh MA; Tang C; Siva S; Berlin A; Hannan R; Warner A; Koontz B; De Meeleer G; Palma D; Ost P; Tran PT
Eur Urol Oncol; 2023 Feb; 6(1):28-38. PubMed ID: 36283936
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
Cuccia F; Tamburo M; Piras A; Mortellaro G; Iudica A; Daidone A; Federico M; Zagardo V; Ferini G; Marletta F; Spatola C; Fazio I; Filosto S; Pergolizzi S; Ferrera G
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629732
[No Abstract] [Full Text] [Related]
17. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
18. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
[TBL] [Abstract][Full Text] [Related]
19. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
20. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
